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1. Introduction 
1.1 The B-cell response in autoimmune disease1 
The pathological effects of autoimmune diseases on the target tissues can be mediated by 
autoantibodies, cell-mediated immune responses, or both. It is increasingly evident that some 
autoimmune diseases previously thought to be essentially T-cell-mediated also have a B-cell 
component, which may involve direct effects of autoantibody secreted by plasma cells, pro- or 
anti-inflammatory cytokines secreted by activated effector or regulatory B-cells, or through the 
highly efficient antigen presentation function of B-cells enabling them to activate CD4+ T-cells 
and vice versa. The number of autoimmune diseases known to be mediated partly or largely 
through autoantibodies has increased markedly in recent times. Systemic lupus erythematosus 
(SLE)1, in which the pathology is mediated via Type II & III hypersensitivity reactions 
involving anti-DNA autoantibodies, has long been known to fall into this category. Many 
other autoantibodies are produced by these patients, principally against nuclear antigens, but 
most are not thought to be involved in pathology. Hashimoto’s thyroiditis and Graves’ disease 
patients produce pathogenic autoantibodies against thyroid antigens, the latter being a rare 
example of an activating autoantibody inducing signalling via the thyroid stimulating 
hormone receptor. Myasthenia gravis patients produce autoantibodies against the 
acetylcholine receptor (AChR), present on the motor muscle endplates, thereby inhibiting 
muscle contraction. Anti-SS-A and anti-SS-B (anti-Ro & anti-La) autoantibodies are implicated 
in congenital heart block in children born to mothers with Sjögren’s Syndrome due to 
transplacental uptake of IgG autoantibodies; autoantibodies against ǂ-fodrin are also believed 
to be pathogenic in these patients. Rheumatoid arthritis (RA), one member of the group of 
systemic rheumatic autoimmune diseases that also includes SLE, psoriatic arthritis and the 
various forms of myositis, has now gone full cycle in views on its pathological mechanisms. 
                                                 
1 Abbreviations: AChR, Acetylcholine Receptor; AID, Activation Induced Cytidine Deaminase;  AMC, 
Arthrogryposis Multiplex Congenita; ARS, Anti-amino acyl-tRNA Synthetase; Bmem, Memory B-cell; 
CDR, Complementarity Determining Region; DM, Dermatomyositis; EOMG, Early Onset Myasthenia 
Gravis; FDC, Follicular Dendritic Cell; G.C., Germinal Centre; IBM, Inclusion Body Myositis; IM, 
Inflammatory Myopathies; LOMG, Late Onset Myasthenia Gravis; MAA, Myositis-Associated 
Autoantibodies; MAb, Monoclonal Antibody; MIR, Main Immunogenic Region; MSA, Myositis Specific 
Autoantibodies; PM, Polymyositis; RA, Rheumatoid Arthritis; SLE, Systemic Lupus Erythematosus; 
TAA, Tumour-Associated Antigen; TIL, Tumour-Infiltrating Lymphocytes; Tfh, Follicular T helper cell; 
UNG, Uracil Nucleotidyl Glycosylase. 
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Initially thought to be caused by the anti-IgG Fc antibody (rheumatoid factor), although 
approximately 25% of RA patients are rheumatoid factor negative, the evidence then swung in 
favour of a cell mediated autoimmune response involving effector T-cells and cytokines, 
principally TNFǂ. Although these are clearly involved in joint pathology, autoantibodies 
against cyclic citrullinated proteins are a much better diagnostic marker for RA than 
rheumatoid factor and there is some limited evidence that they may be pathogenic. It is also 
now recognised that B-cells play an important role in the pathogenic autoimmune response, as 
clearly demonstrated by the marked clinical improvement in patients treated with 
Rituximab®, an anti-CD20 chimaeric (human/mouse) monoclonal antibody that suppresses B-
cell responses. Other autoimmune diseases with B-cell involvement include autoimmune 
haemolytic anaemia, idiopathic thrombocytopaenia, Type I diabetes, and some subtypes of 
myositis, although the situation is often confused by the presence of non-pathogenic 
autoantibodies. 
1.2 The germinal centre response to foreign antigens 
Germinal centres (g.c.) are the main sites of generation of high affinity, antibody-secreting 
plasma cells and Ig class-switched memory B-cells during T-cell-dependent immune 
responses, extensively reviewed by others (Allen, Okada, & Cyster, 2007; Brink, 2007; 
Hauser, Shlomchik, & Haberman, 2007; Klein & Dalla-Favera, 2008; Leavy, 2010; Minton, 
2011). Here we shall summarise briefly the principal features of the g.c. response. The 
response is initiated by B-cells binding to their cognate antigen on the surface of antigen 
presenting cells, such as dendritic cells, in a secondary lymphoid organ (lymph node, 
spleen, Peyer’s patches or human tonsil). The antigen becomes internalised, degraded into 
peptides which are expressed on the cell surface bound to MHC Class II and presented to a 
helper T (Th) cell that provides costimulatory activation signals, including binding of the B-
cell surface molecule CD40 to its ligand, CD154, on the T-cell membrane.  
This interaction takes place at or near the interface between the B-cell follicle and the T-cell 
area and some activated B-cells proliferate outside the follicle and differentiate into short-lived 
plasma cells secreting IgM antibodies. Others migrate into the B-cell follicle where they 
proliferate and differentiate into centroblasts expressing low levels of surface Ig. This region 
develops into a germinal centre with a dark zone of densely packed, proliferating centroblasts, 
and a light zone of more loosely packed B-cells (centrocytes) interspersed with the processes of 
follicular dendritic cells (FDC, Figure 1A). These have distinct stromal origins, unlike the bone 
marrow derived, extra-follicular dendritic cells; almost uniquely, their C’ and Fc receptors trap 
immune complexes and retain antigens in their native state for months.  
The pre-existing IgM+,IgD+ follicle B-cells are pushed out to form a mantle zone around the 
developing germinal centre, the whole structure being termed a secondary follicle. 
Proliferation of the dark zone centroblasts is extremely rapid, with cell cycle times estimated 
at between 6 and 12 hours. These proliferating clones of B-cells switch on the molecular 
machinery required for somatic hypermutation of their rearranged, expressed, Ig V-genes, 
including expression of activation-induced cytidine deaminase (AID). This induces 
mutations specifically targeted to the Ig V-genes at a frequency of 1 per 1000 base pairs per 
cell division, although much lower levels of mutation can also occur in some other, non-Ig 
genes such as Bcl-2 & Bcl-6. AID deaminates cytidine to uracil at C/G base pairs, 
introducing mismatches in the DNA that can be replaced by T/A base pairs. Uracil 
nucleotidyl glycosylase (UNG) can remove the uracil leading to insertion of any of the four 
bases at the abasic site; mismatch repair enzymes also recognise the mismatch and induce 
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single strand breaks which are repaired by error prone DNA polymerases (Di Noia & 
Neuberger, 2007). The mutations are targeted mainly to the complementarity determining 
regions (CDRs) which are intimately involved in binding to the epitope and therefore 
determine specificity and affinity of the antibody. Combined with the rapid proliferation, 
this results in clones of B-cells expressing receptors with a variety of affinities for the 
antigen, some high, some low; some will have lost the ability to bind to the antigen 
altogether and rare B-cells may cross-react with a self-antigen.  
Several clones of proliferating, mutating B-cells are usually present within each germinal 
centre. These cells differentiate into centrocytes expressing mutated antigen receptors and 
migrate into the light zone. The centrocytes move through the light zone, acquire antigen for 
a second time from immune complexes on the follicular dendritic cells, which they 
internalise, process and present to follicular helper T-cells (Tfh-cells) (Patakas et al., 2011), 
thereby receiving survival signals, probably via costimulatory molecule interactions 
including CD40/CD154 and CD80/CD28 binding. These signals, together with Tfh-cell 
cytokines (IL-4 and IFNǄ) and AID deamination of cytidines, promote induction of class 
switch recombination (Patakas et al., 2011). Some of these centrocytes differentiate directly 
into plasmablasts and antibody-secreting plasma cells; others differentiate into Ig class 
switched memory B-cells, both of which migrate out of the follicle. Competition for limiting 
availability of antigen results in selection of B-cells expressing high affinity antigen 
receptors; recent evidence has shown that a broad range of mutations is involved in 
selection, not only for high affinity receptors but also for stability and expression of the B-
cell receptor (Weiser et al., 2011). Cells expressing antigen receptors with low affinity are 
unable to compete for survival signals and the default response is that they die by apoptosis 
and are engulfed by macrophages, in which their degenerating nuclei are visible as tingible 
bodies. Most of this information is derived from studies in mice, in which the germinal 
centres reach maximum size about two weeks after immunisation and then gradually 
decline in the absence of further immunisation, disappearing after several weeks. Although 
the cell composition and structure of secondary follicles appear similar in Man, the kinetics 
and some of the detailed cellular interactions may differ. 
Detailed studies of the kinetics and cellular interactions within germinal centres using 
multiphoton microscopy of living tissue in combination with B & T-lymphocytes expressing 
defined antigen receptors from transgenic animals have revealed much more dynamic activity 
than was previously suspected. It is now recognised that there is less distinction between the 
dark and light zones than suggested by static immunohistological examination, and there is 
continual recycling of B-cells both between and within the two zones, although there is net 
migration from the dark zone to the light zone (Beltman et al., 2011)(Figure 1B). Centrocytes 
move rapidly through the network of follicular dendritic cell processes, apparently sampling 
the immune complexes attached to their membranes and some of these cells return to the dark 
zone for further rounds of proliferation and somatic hypermutation. Migration of B-cells 
between the zones is controlled by chemokines, possibly secreted by stromal cells within the 
germinal centre. Tfh-cells are present mainly in the light zone and recent data suggest that 
affinity selection of B-cells may involve competition for signals from cognate Tfh-cells via 
peptide/MHC Class II binding as well as, or instead of, competition for antigen on the surface 
of follicular dendritic cells (Victora et al., 2010). Anti-self B-cells that have escaped negative 
selection in the bone marrow, or have arisen in the germinal centre due to somatic 
hypermutation, are either eliminated at this stage, suppressed by regulatory T-cells, or alter 
their antigen specificity by receptor revision, a process similar to V-gene rearrangement in 
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developing B-cells. This involves re-expression of RAG1 and RAG2 and rearrangement of an 
upstream light chain V-gene to an unused J exon (Nemazee, 2006). Despite the absence of D 
exons in the rearranged heavy chain locus, we have shown that an upstream heavy chain V-
gene can also replace all or part of a rearranged VH-gene, thereby altering the specificity of the 
receptor away from self antigen (Darlow & Stott, 2005). The architecture, cellular components 
and processes occurring in a typical germinal centre are summarised in Figure 1. 
 
 
Fig. 1. Diagrammatic representation of a germinal centre in a lymph node. 
A: Showing a dark zone containing proliferating clones of mutating centroblasts and a light zone 
containing centrocytes in contact with follicular dendritic cells and follicular helper T-cells (Tfh cells). 
Long-lived memory B-cells, plasmablasts and plasma cells secreting antibody molecules migrate out of the 
g.c. and leave the lymph node via the efferent lymphatic vessel. Apoptotic B-cells, macrophages containing 
tingible bodies and the mantle zone are not shown.  
B: The same germinal centre showing recirculation of B-cells within and between the dark and light zones. 
1.3 The ectopic germinal centre response in autoimmune disease  
It has been known for many years that the target tissues of autoimmune diseases contain 
infiltrating lymphocytes and other immune cells, including T-cells, B-cells, plasma cells, 
macrophages, dendritic and follicular dendritic cells. In many cases the infiltrating cells 
organise themselves into structures resembling germinal centres. Some of these have a mantle 
zone, suggesting that they were formed from a primary follicle whereas, even when absent, it 
is often possible to distinguish a dark zone, containing few or no CD4+ T-cells or follicular 
dendritic cells, and a light zone containing both. Autoantigens have been identified on the 
finger-like processes of follicular dendritic cells (Shiono et al., 2003) and, in some cases, 
autoantibodies have been identified in g.c. B-cells. Separate T-cell areas containing dendritic 
cells and, sometimes, high endothelial venules, can also be seen. The stage of lymphoid 
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neogenesis appears to be directly related to the extent of infiltration of lymphoid and other 
immune cells (Aloisi & Pujol-Borrell, 2006). Examples of autoimmune diseases in which 
germinal centre-like structures have been identified in the target, or disease-related tissues are 
shown in Table 1. It is now apparent that ectopic germinal centres, also known as tertiary 
lymphoid organs, can also develop in other chronic inflammatory diseases, such as the gut in 
Crohn’s disease and ulcerative colitis patients, in chronic infections (Aloisi & Pujol-Borrell, 
2006) and some types of cancer (Table 1). The questions these observations raise are: 1. How do 
they develop?; 2. How closely do they resemble germinal centres in secondary lymphoid 
organs?; 3. Are the B-cells within them undergoing a germinal centre response, as described in 
section 1.2 above?; 4. Are they generating plasma cells secreting pathogenic autoantibodies?; 5. 
What role do they play in the pathogenesis of autoimmune disease? 
 
Autoimmune Diseases Organ containing 
Germinal Centres 
Antigen(s) Recognised 
by GC B-cells 
Reference 
Hashimoto’s thyroiditis Thyroid Thyroglobulin, 
Thyroperoxidase 
(Knecht, Saremaslani, & 
Hedinger, 1981) 
(Armengol et al., 2001) 
Graves’ disease Thyroid Thyroglobulin, 
Thyroperoxidase 
(Armengol et al., 2001) 
Myasthenia gravis Thymus Acetylcholine receptor (Yoshitake et al., 1994) 
(SHIONO et al., 2003) 
Sjögren’s syndrome Salivary glands SS-A (Ro), SS-B (La) (Stott et al., 1998) 
Rheumatoid arthritis Synovial membranes 
of joints 
IgG Fc, Cyclic citrullinated 
protein/peptide 
(Manzo & Pitzalis, 2007)  
(Humby et al., 2009) 
Psoriatic arthritis Synovial membranes 
of joints 
? (Canete et al., 2007) 
(Gerhard et al., 2002)  
Cryptogenic fibrosing 
alveolitis 
Lungs ? (Wallace et al., 1996) 
Uveoretinits Choroid of the eye ? (Liversidge et al., 1993) 
Autoimmune hepatitis Liver ? (Mosnier et al., 1993) 
Multiple sclerosis Meninges (?) ? (Prineas, 1979) (Serafini et al., 2004) 
    
Chronic Inflammatory 
Diseases 
   
Crohn’s disease Gastrointestinal tract ? (Kaiserling, 2001) 
Ulcerative colitis Descending colon ? (Kaiserling, 2001) 
    
Infectious Diseases    
Chronic hepatitis C infection Liver ? (Mosnier et al., 1993) 
Helicobacter pylori or 
Campylobacter gastritis 
Stomach Bacterial antigens (Genta, Hamner, & Graham, 1993) 
(Stolte & Eidt, 1989) 
Chronic Lyme disease Synovial membranes of 
joints 
? (Ghosh et al., 2005) 
Oncocerciasis Skin ? (Brattig et al., 2010) 
    
Cancers    
Lymphoma of MALT 
associated with Sjögren’s 
Syndrome 
Lymphoma ? (Bombardieri et al., 2007a) 
Ductal breast carcinoma Breast tumour Epidermal growth factor 
receptor family 
(Coronella et al., 2002) 
(Nzula, Going, & Stott, 2003a) 
(Simsa et al., 2005) and section 5. 
Medullary breast carcinoma Breast tumour Ganglioside (Coronella et al., 2001) 
(Kotlan et al., 2005) 
Table 1. Diseases in which ectopic germinal centres have been observed. 
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It has now been shown by combined immunohistochemistry, identification of antigen 
specificity of B-cells and plasma cells in and around ectopic germinal centres, and sequence 
analysis of expressed, rearranged Ig V-genes and their somatic mutations, that germinal 
centre B-cells in the target tissues of several autoimmune diseases are undergoing clonal 
expansion, somatic hypermutation and affinity selection, in a similar manner to that seen in 
the germinal centres of secondary lymphoid organs (Table 1 and section 1.2). This has been 
demonstrated in Sjögren’s syndrome, rheumatoid arthritis, psoriatic arthritis, myasthenia 
gravis, multiple sclerosis and also in breast cancer. In some of these cases, expression of 
RAG1 and 2 have been observed (Armengol et al., 2001), indicating that receptor revision 
also takes place in ectopic germinal centres and therefore the generation and attempted 
elimination of self-reactive B-cells. The signals involved in tertiary lymphoid organ 
neogenesis appear to be similar to those in development of secondary lymphoid organs, 
although the temporal and causal relationship between appearance of these structures in the 
target tissue and autoimmune pathology-related tissue damage is unclear. One scenario is 
that an initial event in the tissue, which could, in some cases, include microbial infection, 
leads to the release of molecules seen by the immune system as “danger signals” 
(Matzinger, 2007) thereby inducing infiltration of inflammatory cells and subsequent 
lymphoid neogenesis, causing further tissue damage with concomitant release of self-
antigens, more danger signals and a vicious cycle, perpetuating a chronic autoimmune 
reaction. Alternatively, initial tissue damage may be caused by an autoimmune response 
commencing in the secondary lymphoid organs, with subsequent events following a similar 
course to that described above. Lymphotoxins ǂ, ǃ, ǂ1ǃ2 and TNFǂ have been shown to be 
required for development of ectopic germinal centres. Growth-factor receptor-bound 
protein-2 (Grb2) has recently been shown to control orthotopic lymphoid follicle 
organisation and the germinal centre response by inducing production of lymphotoxin-ǂ via 
CXCR5 signalling (Jang et al., 2011). These molecules are secreted by infiltrating B and Th1-
cells and activated NK cells; on binding to their receptor on stromal cells they induce 
expression of adhesion molecules and secretion of chemokines which induce further 
lymphocyte infiltration and segregation into B-cell follicles, formation of a follicular 
dendritic cell network and T-cell areas. It has also recently been proposed that 
overexpression of costimulatory molecules on Tfh-cells may contribute to overcoming B-cell 
tolerance (Patakas et al., 2011). This may be a contributory factor in ectopic as well as 
orthotopic germinal centres. Primary B-cell follicles are rarely seen in autoimmune disease 
target tissues but this may be because chronic antigen stimulation has been in progress for a 
considerable time before biopsies are taken. For example, in type I diabetes mellitus there is 
evidence that the autoimmune response develops long before overt disease is diagnosed. 
Whether ectopic germinal centres are initiated by naïve or memory B-cells is unclear but 
recent evidence shows that at least some B-cell clones arise de novo from naïve B-cells (Sims 
et al., 2001; Nzula, Going, & Stott, 2003b; Nzula, Going, & Stott, 2003a). 
The frequency of ectopic germinal centres varies markedly between autoimmune diseases; 
as one might expect, the highest incidence is in diseases where pathogenic autoantibodies 
are most strongly implicated. Thus, they have been identified in thyroid tissues of 100% of 
Hashimoto’s thyroiditis patients and 54 – 63% of Graves’ disease cases; in rheumatoid 
arthritis the figure is 25 – 50% but in Sjögren’s syndrome it is only 17%, although variations 
may to some extent reflect differences in the difficulty of finding the germinal centres. In 
Sjögren’s syndrome, the source is usually biopsies of the small labial salivary glands of 
which there is a large number; as g.c.s are only present in some of the many small labial 
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salivary glands, they may easily be overlooked. Tissues containing different types of cells 
respond in a variety of ways to inflammatory signals and this may also determine whether, 
and to what extent, lymphoid organ neogenesis occurs. The origin of follicular dendritic 
cells is unclear but it has been proposed that they develop from precursor cells already 
present in the tissue, either fibroblasts or fibroblast precursor cells (Park & Choi, 2005). 
Alternatively, the precursor cells may be induced to migrate into the tissue by the same or 
similar chemokines as those attracting the B and T-lymphocytes. In several autoimmune 
diseases (Table 1) and animal models of autoimmune diseases (Astorri et al., 2010; 
Nacionales et al., 2009), it has been demonstrated that ectopic germinal centres are 
generating plasma cells secreting pathogenic autoantibodies and, almost certainly, memory 
B-cells bearing anti-self antigen receptors, implying that they aid the diversification of the 
autoantibody repertoire and contribute to the maintenance of immune pathology. In 
addition to autoantibody production, self-reactive B-cells generated in ectopic germinal 
centres may also contribute to autoimmune pathology by secretion of pro-inflammatory 
cytokines and activation of pathogenic T-cells by presentation of processed self-antigens. B-
cells may contribute in this way to immune pathology in autoimmune diseases generally 
considered to be principally T-cell mediated, and may be one explanation for the efficacy of 
Rituximab therapy for rheumatoid arthritis. 
2. Methods 
2.1 Identification and cellular composition of ectopic germinal centres 
The methods we used to identify ectopic germinal centres, characterise their cellular 
composition, analyse the rearranged Ig V-gene sequences expressed by germinal centre B-
cells and identify their antibody specificity have been described in detail in previously 
published papers (Nzula, Going, & Stott, 2003a; Sims et al., 2001). Briefly, sections were cut 
from snap frozen tissue biopsies and every tenth section stained for B-cells with anti-CD20. 
Sections containing germinal centre-like structures or B-cell aggregates were further 
characterised by staining for T-cells (anti-CD3, CD4, CD8), regulatory T-cells (anti-FoxP3), 
follicular dendritic cells (anti-FDC (DAKO) or anti-CD35), plasma cells (DAKO), 
macrophages (anti-CD68) and proliferating cells (anti-Ki67). Double immunofluorescent 
staining with the above cell subset-specific antibodies and Ki67 was used to identify 
dividing cells. Acetylcholine receptor-specific B-cells in germinal centres from the thymus of 
myasthenia gravis patients were identified by 125I-ǂ-bungarotoxin-labelled acetylcholine 
receptor and autoradiography (Shiono et al., 2003; Hill et al., 2008); other autoantibody-
producing cells were identified by immunofluorescence staining with the relevant antigen. 
2.2 Cloning and sequence analysis of rearranged Ig V-genes 
Ectopic germinal centres and B-cell aggregates were excised by microdissection, digested 
with proteinase K and the released DNA used as a template for amplification of the 
rearranged Ig V-genes by nested PCR. Details of the method and the primers are described 
in Sims et al. (2001) and Nzula et al. (2003). Amplified DNA was purified by agarose gel 
electrophoresis, ligated into plasmid DNA and cloned in E. coli. Cloned plasmid DNA was 
purified and the Ig V-genes sequenced in both directions using primers complementary to 
sequences flanking the cloning site. The best matching germline V, D & J sequences were 
identified initially by comparison with the VBASE directory of human Ig V-genes and later, 
after VBASE ceased to be updated, using the Immunogenetics (IMGT) Database of Human 
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Immunoglobulin Sequences (http://www.imgt.org/). Sequences were analysed using 
JOINSOLVER (http://joinsolver.niaid.nih.gov/) and IMGTV-QUEST. Silent and 
replacement somatic mutations were identified by comparison with the germline gene 
sequence; in early experiments the ratio of replacement to silent mutations was considered 
to be evidence of affinity selection if significantly higher than 3:1. To correct for the inherent 
bias towards replacement mutations in CDRs, we have more recently applied the method of 
Hershberg to determine whether affinity selection has occurred in B-cell clones from ectopic 
germinal centres (Hershberg et al., 2008). This method employs an algorithm that allows for 
the effects of microsequences in the complementarity determining regions (CDRs) and the 
bias towards transition mutations. Clonally related sets of rearranged V-genes were 
identified by their use of the same germline V, (D) and J exons and shared junctional 
sequences. Genealogical trees were constructed by analysis of shared and unshared 
mutations using the parsimony method of phylogenetic analysis (PAUP, (Swofford, 1993)), 
enabling the assignment of sequences from parent and daughter cells that have been 
produced during clonal proliferation, thus providing clear evidence of the presence of 
clonally proliferating, somatically mutating B-cells within the germinal centre. 
2.3 Cloning antigen-specific autoantibodies from germinal centre B-cells by ‘phage 
display 
In order to confirm the antigen specificity of B-cells generated in ectopic germinal centres, 
and to analyse in detail the relationship between their mutations and antigen specificity, we 
reconstituted the rearranged Ig V-genes as single chain Fv (scFv) or Fab antibodies by 
‘phage display. Single chain Fv antibodies comprise the heavy and light chain variable 
region domains linked by a short peptide. Although linked together by a short additional 
peptide sequence, the VH and VL domains are able to fold into their natural 3-dimensional 
conformation and pair correctly, as the antibody produced by a B-cell or plasma cell. They 
contain the antigen binding site, and therefore mimic the antigen specificity of the original 
antibodies from which they were derived. A caveat that must be born in mind is that the 
original H and L chain pairings are unknown, except when both genes are cloned from a 
single cell. The detailed methodology has been described elsewhere (Stott & Sims, 2000; 
Matthews et al., 2002). Rearranged VH and VL-genes amplified either from microdissected 
germinal centres or pooled V-genes from the same B-cell clone, were used to construct scFvs 
using a (Gly4Ser)3 linker DNA. The resulting scFv library, comprising a pool of randomly 
linked VH-VL genes, was then inserted into the phagemids pCANTAB6 or pHEN2 
continuously with the gene encoding the bacteriophage coat protein P3, and grown in E. coli 
in the presence of helper phage. The resulting scFv-P3 fusion protein was expressed on the 
surface of bacteriophage or as soluble scFv by transfection into a non-permissive, or 
permissive, strain of E. coli respectively. Alternatively, Fab libraries were constructed using 
whole light chain cDNA and DNA encoding the VH region and the first constant region 
domain of the heavy chain by similar techniques (Matthews et al., 2002). An advantage of 
amplifying directly from genomic DNA is that the distribution of cloned V-genes reflects the 
usage of those genes by B-cells and plasma cells more accurately than amplification from 
cDNA, which is biased towards plasma cells. The library of scFvs or Fabs attached to 
bacteriophage by the P3 ‘phage coat protein was then panned on plastic plates coated with 
either a whole extract of the target tissue, or purified recombinant antigen, to identify self-
reactive antibodies. Bound ‘phage were washed, eluted, re-grown in E. coli and panning 
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repeated until the eluate had become enriched with a small number of ‘phage clones. These 
were recloned and their H & L chains sequenced and used to investigate the specificity and 
properties of their antigen-binding sites. 
2.4 Statistical analysis 
The method of Hershberg et al. (2008), described in section 2.2 above, was used to determine 
the significance of replacement mutations in rearranged Ig V-genes cloned from germinal 
centre B-cells, as evidence for affinity maturation of the antibodies expressed by them. The 
distribution of VH gene families and individual V, D and J exons was assessed using two-
tailed 2 analysis, corrected for multiple comparisons. 
3. The ectopic germinal centre response in myasthenia gravis 
3.1 Pathology of myasthenia gravis 
Myasthenia gravis is an organ-specific autoimmune disease characterised by weakness of 
striated muscles and thymic hyperplasia (Vincent, 2002). Patients are generally divided into 
subgroups with early-onset (EOMG, pre-40 years) or late onset (LOMG, post-40 years) forms 
of the disease, or with thymoma in about 10% of patients. It is a classic autoantibody-
mediated autoimmune disease, caused by autoantibodies directed against the postsynaptic 
nicotinic acetylcholine receptor (AChR) at the neuromuscular junction. Many thymoma 
patients and some late onset patients also have serum antibodies against striated muscle 
antigens, interferon-ǂ and IL-12. Loss of functional AChRs leads to muscle weakness, 
usually first evident in weakness of eye movement. This can progress to other striated 
muscles of the body, causing problems with breathing due to effects on the diaphragm, 
swallowing difficulties and paralysis. These effects can be life-threatening if untreated. 
Evidence that the effects are mediated by autoantibodies against the AChR include 
induction of similar symptoms by: their transfer from mother to baby in utero; passive 
transfer from patients to mice; immunisation of animals with AChR; and marked 
improvement of symptoms in patients after removal of circulating IgG antibodies by 
plasmapheresis. Several pathogenic mechanisms are involved (Vincent, 2002; Drachman, 
1994): (i) Cross-linking of the receptor by autoantibodies causes loss of AChR by antigenic 
modulation, leading to internalisation and degradation of the receptors; (ii) The majority of 
anti-AChR antibodies are of the IgG1 and IgG3 subclasses, which are particularly efficient at 
complement activation, resulting in lysis and damage to the muscle membrane; (iii) Less 
commonly, some antibodies cause direct inhibition of the ion channel function of the AChR; 
(iv) Antibody-dependent cell-mediated cytotoxicity has also been implicated, although there 
is little direct evidence for this mechanism. The IgG autoantibodies can cross the placenta of 
pregnant mothers with myasthenia gravis by an active transport mechanism involving the 
neonatal Fc receptor, FcRn, resulting in transient symptoms of myasthenia gravis in the 
newborn infant. The symptoms gradually ameliorate as the maternal antibodies are 
catabolised and replaced by the infant’s own antibodies. More rarely, the autoantibodies 
produced by multiparous mothers can induce severe, often fatal, developmental 
abnormalities, termed arthrogryposis multiplex congenita, due to paralysis of fetal muscles 
in utero (see section 3.4.5).  
3.2 Structure and epitopes of the acetylcholine receptor 
The AChR is a pentameric transmembrane glycoprotein found almost exclusively at the 
muscle endplate, comprising two ǂ polypeptide subunits, one ǃ, one ǅ and, in the adult, one 
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ǆ subunit; in the fetus there is also one Ǆ subunit, which is gradually replaced by an ǆ from 
the third trimester onwards (Fig. 2) (Vincent, 2002). The five subunits are combined into a 
cylindrical structure with a central cation channel that is closed in the inactive conformation. 
There are two binding sites for acetylcholine, formed at the interfaces between one ǂ and ǅ 
subunit and the second ǂ and ǆ or Ǆ subunits. Electrical impulses passing down the motor 
nerve trigger release of acetylcholine molecules at the nerve termini. When these bind to the 
two receptor binding sites, they cause the central cation channel to open and sodium ions to 
flood into the muscle resulting in local membrane depolarisation. When this reaches 
threshold the resulting action potential spreads across the muscle triggering it to contract. 
Loss of at least 50% of receptors is required to produce overt muscle weakness. 
 
 
Fig. 2. Diagrammatic representation of the structure of the acetylcholine receptor: 
(a) the complete pentameric molecule in the cell membrane; (b) the topology of the subunits, illustrated 
for the ǂ subunit that contributes to the acetylcholine/ǂ-bungarotoxin binding site, the main 
immunogenic region (MIR) and the very immunogenic cytoplasmic epitope (VICE); It is doubtful 
whether the latter plays any significant role in pathogenesis; (c and d) the fetal and adult subtypes of 
AChR. Reproduced with permission from (Vincent et al., 1997), Plenum Press. 
Since the patients’ autoantibodies are almost exclusively specific for the complex native 
conformation of the extracellular AChR subunit domains, and not short peptides or even 
whole subunit polypeptides, mapping of the autoantibody epitopes has proved to be 
difficult. The antibodies are mainly IgG1 or IgG3, of high avidity and heterogeneous in their 
sequences and fine specificity. Disease severity correlates poorly with autoantibody titre, 
suggesting that pathogenicity may depend upon precise epitope specificity. Many of the 
antibodies bind to a region of the extracellular domain of the ǂ chain, the main 
immunogenic region or MIR. Its conformation is affected by the ǆ ↔ Ǆ interchange, as 
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demonstrated by the observation that some antibodies bind better to the MIR of the fetal 
AChR than the adult form, even though the Ǆ and ǆ subunits do not contribute directly to 
the MIR (Fostieri, Beeson, & Tzartos, 2000). Titres of MIR antibodies vary considerably 
between patients and other antibodies may play an equally important role in some 
individuals. Some patients also produce autoantibodies against the acetylcholine binding 
sites (that also bind ǂ-bungarotoxin); these are the blocking antibodies described above. 
3.3 Role of the thymus 
Early onset myasthenia gravis is associated with thymic hyperplasia characterized by 
secondary lymphoid organ-like structures in the medulla of >90% of patients. These include 
T-cell areas containing AChR-specific helper T-cells and large numbers of germinal centres 
with clearly defined mantle, dark and light zones. Plasmablasts and plasma cells secreting 
autoantibodies against AChR are also detectable within and around the germinal centres 
(Hill et al., 2008; SHIONO et al., 2003). Approximately 20% of germinal centres contain 
plasmablasts positive for antibodies against AChR and AChR is trapped on follicular 
dendritic cells in c.50% of thymic germinal centres (SHIONO et al., 2003). Anti-AChR-
secreting hybridomas and AChR-specific Fabs have been cloned from thymic B-cells and 
thymectomy results in a reduction in the serum anti-AChR titre and reduced clinical 
symptoms in some patients, although the benefits of thymectomy have never been 
rigorously proved (Cardona et al., 1994; Farrar et al., 1997; Graus et al., 1997). The relative 
contribution of the thymus to production of anti-AChR autoantibodies compared with the 
secondary lymphoid organs is unknown, but it appears to play a significant role. Therefore, 
using the methods described in section 2, we tested the hypothesis that thymic germinal 
centres are sites of ongoing autoimmune responses driven by autoantigen, i.e. sites of 
activated B-cells, clonally proliferating, somatically mutating their expressed Ig V-genes and 
undergoing affinity maturation, driven by the acetylcholine receptor. 
3.4 The thymic germinal centre response in myasthenia gravis 
3.4.1 Germinal centres in the thymus 
Thymi from 5 EOMG patients were examined by immunohistology. All 5 contained large 
numbers of germinal centres with typical mantle zones within the thymic medulla, 
histologically indistinguishable from germinal centres in human tonsil controls. The mantle 
zones contained densely packed CD20+ B-cells surrounding the germinal centre B-cells (Fig. 
3A). These were interspersed with a network of follicular dendritic cells extending 
throughout the dark and light zones (Fig. 3C) and a crescent of T-cells can be seen at the 
apex of the light zone (Fig. 3B). Proliferating B-cells were distributed throughout the 
germinal centre but in larger numbers within the dark zone (Fig. 3D). Autoradiography with 
125I-ǂ-bungarotoxin alone, which binds to AChR, diffusely labelled c.50% of germinal 
centres and appeared to be associated with the follicular dendritic cell processes. No 
labelling was seen in human tonsils or thymi from two seronegative myasthenia patients 
and bungarotoxin binding was blocked by the cholinergic drug, carbamyl choline, which is 
structurally similar to AChR, indicating that the follicular dendritic network contained 
membrane-bound antigen or immune complexes.  
In contrast, 125I-ǂ-bungarotoxin-labelled AChR bound to individual cells in 20% of germinal 
centres, including large numbers of moderately labelled centrocytes in the light zone, 
smaller numbers in the dark zone, and heavily labelled plasmablasts/plasma cells in and 
around the germinal centres (Fig. 3E & F).  
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Fig. 3. Immunohistochemically stained serial sections through thymic germinal centres. 
A & B: Germinal centres stained (red) with anti-CD20 and anti-CD3 for B and T-cells respectively. The 
arrow (B) shows a crescent of T-cells in the light zone. C: A network of follicular dendritic cell processes 
is spread throughout the germinal centre, including both the light and dark zones. D: Germinal centre 
cells stained with an antibody against proliferating cell nuclear antigen, revealing dividing B-cells in 
both areas but more concentrated in the dark zone. E & F: 125I-ǂ-bungarotoxin-labelled AChR reveals 
individual AChR-specific plasmablasts/plasma cells in and around germinal centres (detected by 
autoradiography). Diffuse labelling in the light zone probably indicates binding of free 125I-ǂ-
bungarotoxin to AChR trapped on follicular dendritic cells (see text). Reproduced from Sims et al (2001). 
3.4.2 Ig V-gene expression by thymic germinal centre B-cells 
In order to determine whether thymic germinal centre B-cells are subjected to antigen-
driven clonal proliferation, somatic hypermutation and affinity selection, as seen in the 
orthotopic germinal centres of secondary lymphoid organs, we cloned and sequenced 
rearranged Ig heavy chain V-genes from multiple sections through four thymic germinal 
centres (A – D) and the follicular mantle surrounding one of them (A). 216 rearranged VH-
genes, derived from 61 independently rearranged, functional sequences, were obtained from 
the four germinal centres and 46 VH-genes from the follicular mantle were derived from 24 
functional VH-genes. Since the PCR error rate in control experiments was estimated to be 
less than one base per four VH-genes, only sequences using the same V, D & J exons, the 
same junctional sequences and a minimum of one base difference per gene, were accepted 
as mutated members of a clonally related set of B-cells. This conservative assessment almost 
certainly discards some B-cell clones with low frequencies of somatic mutation and therefore 
underestimates the true B-cell diversity. When calculating the number of VH-genes used, 
members of the same B-cell clone were counted only once. However, this reflects the 
number of individual B-cell clones and non-dividing B-cells rather than the total number of 
B-cells using a particular gene. 
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The distribution of VH-gene families was similar in the follicular mantle and all four 
germinal centres, with predominant use of members of the VH3 gene family compared with 
the number of germline VH-genes in this family (Fig. 4A). However, since this gene family is 
also predominantly used by the peripheral blood B-cells of healthy individuals, it was not 
considered to be significant. No VH6, VH7 or JH2 genes were isolated and JH1 was under-
used, but the rarely used VH5-51 gene and the JH4 exon (Fig. 4B) were over-represented, both 
being used by rearranged V-genes from three different germinal centres in combination 
with different D exons (DH2-2, DH5-12 and DH-6-19). In many cases the D exon could not be 
identified due to junctional diversity and removal of bases during recombination. Of those 
that could be identified, DH3 and DH6 were the most commonly used. These data strongly 
imply selection for B-cells expressing antigen receptors using particular combinations of V, 
D and J segments, despite the heterogeneity of the germinal centre B-cells. This would be 
even more apparent if individual members of the same B-cell clone were counted separately. 
 
 
Fig. 4. Frequency of usage of VH and JH germline genes by thymic germinal centre B-cells. 
A: The frequency of VH gene family usage in all germinal centres analysed differs significantly from 
predictions from the number of members of each family in the germline. Members of clonally related 
sets were only counted once. B: The frequency of individual JH exon usage in all germinal centres 
analysed differs significantly from the number of JH exons in the germline (*p<0.01). Reproduced from 
Sims et al (2001). 
3.4.3 Somatic hypermutation and clonal proliferation of B-cells in thymic germinal 
centres 
All the germinal centres and the follicular mantle contained B-cells expressing both mutated 
and unmutated Ig V-genes, the latter presumably coming from naïve B-cells. The majority of 
V-genes from the germinal centres and the follicular mantle were mutated, with 
considerable variation in the number of mutations, ranging from 0 – 52. Some of the 
rearranged V-genes in clonally related sets had high ratios of replacement to silent 
mutations from 4.7:1 to 7.0:1 in the CDRs, which form the antigen-binding site, suggesting 
affinity selection of mutated antigen receptors is taking place in the germinal centre. Some 
other sequences had low numbers of replacement mutations, suggesting selection against 
replacement mutations, as also found by (Zuckerman et al., 2010). 18 different sets of 
functionally rearranged VH-genes included two or more related sequences sharing the same 
V, D and J segments and junctional sequences but with significantly more than one mutation 
per V-gene and, in three cases, they were cloned in separate amplifications from different 








Fig. 5. Examples of clonally related sets of rearranged VH genes isolated from thymic 
germinal centres C and D. 
The genealogical trees were constructed using the most parsimonious parent-daughter cell relationships 
of clonally related sets of sequences (section 2.2). The best matching germline gene is depicted as an 
ellipse. Letters in the circles refer to individual sequences from the same clonally related set. Deduced 
intermediates are shown as dotted circles. Numbers at the side of the arrows indicate the minimum 
number of mutations required to generate a daughter cell from the immediate parental cell. The results 
show that the B-cells from which they were derived are undergoing antigen-driven clonal proliferation 
and somatic hypermutation from both naïve and memory B-cell precursors. A: B-cell clones from 
germinal centre C; B: B-cell clones from germinal centre D; C: Frequency of mutations in the VH genes 
expressed by the most probable progenitor cells of all 18 B-cell clones analysed. Reproduced from Sims 
et al. (2001). 
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These related sets of V-genes were therefore derived from members of the same 
proliferating B-cell clone, showing that antigen-driven B-cell proliferation and somatic 
hypermutation are taking place within the thymic germinal centres. All of the isolated B-cell 
clones were small, containing a maximum of five members.  
We do not know the total number of clones proliferating within a single germinal centre. 
We examined every tenth section but may have missed small B-cell clones, so there are 
likely to be more than we detected. Genealogical trees of related sets of V-genes were 
constructed by the most parsimonious relationship on the basis of shared and unshared 
mutations (section 2.5). Six of the 18 clones isolated from two germinal centres containing 
AChR-specific B-cells were derived from unmutated precursors, i.e. naïve B-cells, whereas 
the VH-genes of the earliest founder cells isolated from the other 12 clones contained from 
5 to >30 mutations. Examples of six of these clones are shown in Fig. 5. Although we 
cannot rule out the possibility that some of these clones were also derived from 
unidentified naïve B-cells, it is most probable that the majority were generated from 
founder memory B-cells. Thus, both memory and naïve B-cells have been stimulated by 
antigen and are proliferating and mutating their antigen receptors within thymic germinal 
centres of myasthenia patients.  
3.4.4 Evidence for selection of AChR-specific B-cell clones in thymic germinal centres 
Three B-cell clones from 3 different AChR positive germinal centres expressed the rarely 
used VH5-51 genes. Furthermore, these three independent sets of V-genes exhibited the 
same amino acid replacements at three positions. Comparison of our V-gene sequences with 
those of heavy chains from known AChR-specific hybridomas and Fabs revealed some 
common features. Germline genes used by four of our B-cell clones also encode anti-AChR 
antibodies cloned from other EOMG patients, and several of the amino acid substitutions in 
CDR1 and CDR2 from two B-cell clones were also present in an anti-AChR Fab (Sims et al., 
2001; Matthews et al., 2002). It is therefore unlikely that these mutations occurred by chance, 
suggesting that a common selection process for mutants with high affinity for the AChR is 
in operation. 
3.4.5 Evidence for immunisation by the fetal form of acetylcholine receptor 
Babies born to mothers with myasthenia gravis can develop transient symptoms due to 
transplacental transfer of the maternal autoantibodies and, in rare cases, they have severe 
developmental abnormalities, arthrogryposis multiplex congenita (AMC), caused by 
maternal anti-AChR antibodies that inhibit the ion channel function of the fetal AChR, 
causing paralysis during fetal development in utero, whereas the adult form of the 
mother’s AChR is relatively unaffected. Fetal AChR-specific antibodies are particularly 
prevalent in women who have had babies, suggesting that they may be induced by the 
fetus.  
In order to determine the specificity and clonal origins of fetal AChR-specific 
autoantibodies, combinatorial Fab libraries were constructed from cDNA prepared from 
thymic cells of two mothers (M2 and M6) of AMC babies. 25 Fab clones were isolated and 
two clonally related sets were examined in greater detail. All Fabs bound specifically to the 
Ǆ subunit of fetal AChR, except one that recognised the ǃ subunit also present in the adult 
receptor. Sequencing of the fetal-specific Fabs revealed clearly restricted usage of VH, JH, Vǋ 
& Jǋ gene segments and convergent coding mutations. All the Fabs from AMC mother M2 
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used the VH3-07 gene recombined with JH6b and an unidentified D exon in combination 
with various Vǋ genes, suggesting that the heavy chain is the major contributor to AChR 
binding, at least in this case. The VH3-07 segments were mutated and clonally related. Most 
of the Fabs from AMC mother M6 used the same combination of mutated VH3-21 and JH5b, 
with an unidentified D exon, plus a Vǋ02-12/Jǋ4 light chain, which was also used in two of 
the Fabs from M2. In this case, both the VH3-21 and Vǋ02-12 sets of sequences were clonally 
related, suggesting that they may both be derived from the same B-cell clone. The clonally 
related sequences from both sets of Fabs from M2 and M6 contained many shared and 
unshared coding mutations. The apparent founder member of each set of sequences had a 
large number of base differences from the best matching germline V-gene, suggesting that 






Fig. 6. Clonally related sets of rearranged VH & Vǋ genes encoding AChR-binding Fabs 
cloned from thymic cells from AMC mother M6.  
The heavy and light chains were from the same set of Fabs. Genealogical trees were constructed and 
mutations numbered as described in the legend to figure 5. Fab names are shown in the circles, H 
referring to the heavy chain and K referring to the ǋ light chain. Dotted circles represent hypothetical 
intermediates. Numbers at the side of arrows show the minimum number of mutations required to 
generate a daughter cell from its immediate parent. Reproduced from Matthews et al. (2002). 
Several sequences from both clonally related sets of Fabs had many more replacement 
mutations than expected by chance, indicating affinity selection. There was also clear 
evidence of convergent mutations. Many independently rearranged sequences from both 
patients shared consensus mutations. All the Fabs using VH3 genes contained the same 
31S→T mutation and most of the Vǋ02-12 genes contained a 22SRASET28 motif in CDR1. A 
search of the GenBank database of all human Ig sequences found only two other ǋ chains 
containing this motif, suggesting that it is important in determining the specificity of the 
anti-AChR autoantibodies.  
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Since the EOMG thymus contains many typical germinal centres surrounded by mantle 
zones, including clones of proliferating, AChR-specific B-cells, it is clearly a site of 
autoantibody diversification. The B-cells are undergoing somatic hypermutation and affinity 
selection by cognate binding to AChR bound to the membrane processes of follicular 
dendritic cells, which form a network surrounding B and T-cells in the germinal centres. B-
cells expressing high affinity, AChR-specific antigen receptors receive rescue signals from 
follicular dendritic and helper T-cells inducing them to differentiate into antibody-secreting 
plasmablasts and plasma cells that migrate out of the follicles and leave the thymus to enter 
the circulation, in a classical germinal centre type response. The numerous mutations seen in 
some V-gene sequences suggests that Ig class-switched memory B-cells are also generated 
and either leave the thymus, or some may recirculate within the germinal centre, 
undergoing further rounds of somatic hypermutation and affinity selection, consistent with 
the observations of others that recirculation of centrocytes between the light and dark zones 
occurs in orthotopic germinal centres. Several of the B-cell clones we identified were derived 
from highly mutated precursors, which supports this hypothesis. The autoantibodies 
produced by mothers of AMC babies included antibodies specific for the fetal form of the 
AChR, directed against the Ǆ subunit.  
The reason why large numbers of germinal centres producing AChR-specific B-cells and 
plasma cells develop in the thymi of myasthenia gravis patients is unclear, but it is 
possible that the rare thymic myoid cells may be involved. The induction of fetal AChR-
specific antibodies in parous women suggests, at least in some cases, that expression of 
the fetal AChR on thymic epithelial and myoid cells may initiate an immune response, for 
which the patient’s immune system has not been tolerised. Furthermore, generation of 
thymic germinal centres may be induced by a pre-existing proinflammatory cytokine 
environment, including IFNǄ and TNFǂ. These molecules have been shown to upregulate 
expression of AChR subunits in thymic epithelial cells and on the membranes of myoid 
cells (Poea-Guyon et al., 2005). The chemokines CXCL13 AND CCL21 are produced by 
endothelial cells of the afferent lymphatic vessels in the thymus, attracting activated T and 
B-cells, including naïve B-cells, suggesting that this is the mechanism of induction of 
thymic germinal centres (Berrih-Aknin et al., 2009; Le Panse et al., 2006; Meraouna et al., 
2006; Le Panse et al., 2010).  
We therefore propose a two step process for initiation of the autoimmune response in 
myasthenia gravis (SHIONO et al., 2003). In step 1, there is hyperplasia of thymic epithelial 
cells expressing linear AChR epitopes, including the ǂ and ǆ subunits, in the context of the 
MHC Class II antigen HLA-DR52a, a susceptibility factor for EOMG patients. Whereas these 
peptides would normally induce tolerance, an imbalance in regulatory factors and 
expression of costimulatory molecules results in activation of thymic Th-cells against AChR 
epitopes. In step 2, the Th-cells induce an early B-cell response against the linear peptides 
and some of the resulting antibodies cross-react with conformational epitopes of the native 
AChR expressed on the thymic myoid cells, leading to myoid cell damage, release of 
AChR/antibody immune complexes, danger signals, and recruitment of professional 
antigen presenting cells. These stimulate an enhanced B-cell response accompanied by 
formation of germinal centres with production of high affinity, class switched, pathogenic 
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4. Tissue-infiltrating B-cells in inflammatory myopathies 
4.1 Introduction 
The inflammatory myopathies (IM), collectively called myositis, are classified into three 
principal subsets, Dermatomyositis (DM), Polymyositis (PM) and Inclusion Body Myositis 
(IBM) (Bohan & Peter, 1975a; Bohan & Peter, 1975b; Dalakas & Hohlfeld, 2003). Each of these 
disorders is characterised by moderate to severe muscle weakness and muscle fatigue with 
inflammatory mononuclear cell infiltration within the muscle, but each disorder has distinct 
clinical and pathological features. IM can be associated with various autoimmune and 
connective tissue disorders as well as malignancies, the latter being associated with up to 
45% of adult DM patients. 
DM, the most common of the inflammatory myopathies, is a multi-organ disease not only 
affecting skeletal muscle but, often, the skin as well as other tissues and is more commonly 
found in women than men; it also accounts for up to c.85% of all juvenile IM (Rider, 2007). 
DM is characterised by a heliotrope rash on the upper eyelid, face or upper trunk 
accompanying, or more commonly preceding, proximal muscle weakness. Muscle 
inflammation is predominantly perivascular and/or perimysial or in the interfascicular 
septae and around, rather than within, the muscle fascicles. Perivascular atrophy is a 
characteristic feature of DM patients, often in groups at the periphery of the fascicle. In DM, 
muscle lymphocytic infiltrates consist largely of B-cells and CD4+ T-cells (Arahata & Engel, 
1984; Engel & Arahata, 1984) suggesting that DM may be a humorally mediated immune 
response. 
PM and IBM, though separate disorders, are both characterised by scattered necrotic and 
regenerating muscle fibres and endomysial inflammation with invasion and destruction of 
non-necrotic muscle fibres. PM generally becomes evident in adulthood and is best defined 
as a subacute myopathy that evolves over weeks to months and presents with symmetrical 
weakness of the proximal muscles. Its clinical onset is hard to define with no early 
recognition signs such as the rash observed in DM. PM is uncommon as a stand-alone 
disorder and more commonly associates with other autoimmune and connective tissue 
disorders.  
Onset of IBM is usually after the age of 50 and occurs more frequently in men. Muscle 
weakness can be both proximal and distal and is often asymmetrical. Despite similarities 
with PM, distinctive features of IBM include: rimmed vacuoles; groups of atrophic fibres; 
increased lymphocytic invasion of non-necrotic fibres; less frequent myofibre necrosis; and a 
more slowly progressing clinical course with patients being unresponsive to treatment. In 
both disorders, inflammatory infiltrates typically consist of CD8+ T-cells and macrophages 
(Arahata & Engel, 1984; Engel & Arahata, 1984) which invade MHC Class 1 antigen-
expressing muscle fibres, a feature absent in normal muscle tissue, leading to fibre necrosis. 
The muscle fibre invading CD8+ T-cells can be clonally expanded in both PM and IBM 
(Dalakas, 2004; Fyhr et al., 1997; Hofbauer et al., 2003; Mantegazza et al., 1993; Seitz et al., 
2006), which persists over time (Amemiya, Granger, & Dalakas, 2000).  
4.1.1 Autoantibodies associated with myositis 
As with most autoimmune disorders, different autoantibody specificities have been 
described in DM and PM; autoantibodies are generally absent from IBM although they have 
been detected in a small number of cases (Dalakas et al., 1997). They can either be myositis-
specific (MSAs) or myositis-associated autoantibodies (MAAs), which can also be associated 
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with other autoimmune diseases. Most bind to protein or ribonucleoprotein complexes 
involved in protein synthesis, translocation or elongation; MAA target antigens are 
primarily located in the nucleoplasm or nucleolus. The most prevalent MSAs are directed 
against amino-acyl-tRNA-synthetases (ARS), and are associated with a distinctive clinical 
phenotype, anti-synthetase syndrome, characterised by myositis, Raynaud’s phenomenon 
and interstitial lung disease, with a higher mortality. Anti-Jo-1 (anti-histidyl-tRNA 
synthetase) antibodies are the most prevalent in myositis patients (20-30% of patients), while 
the other anti-ARS antibodies are only present in 1-3% of IM patients, and are a diagnostic 
and prognostic marker for disease severity (Mielnik et al., 2006; Zampieri et al., 2005).  
4.1.2 Muscle-infiltrating B-cells in myositis 
As described above B-cells have been found to be prominent within the muscle infiltrating 
cell populations of DM patients and are rarely found, or absent, in the inflamed muscle of 
PM and IBM patients. CD138+ plasma cells have been identified within the infiltrating 
populations, predominantly in the endomysial areas of muscle tissue of PM and IBM 
patients (Greenberg et al., 2002; Greenberg et al., 2005). This was confirmed by sequence 
analysis of immunoglobulin V-genes expressed by laser dissected cells as well as microarray 
studies which showed an abundance of immunoglobulin transcripts.  
The role for B-cells and plasma cells in IM is still currently unresolved, with continuing 
studies providing further insight into the immune mechanisms. The identification of muscle 
infiltrating B-cells, plasma cells and autoantibodies suggests that these diseases may be at 
least partly driven by a loss of B-cell tolerance and, in the case of PM and IBM patients, not 
solely by the oligoclonal expansion of T-cells. We therefore investigated whether there is 
clonal expansion of infiltrating, autoantibody producing B-cells in situ in IM.  
4.2 The muscle infiltrating B-cell response in myositis 
4.2.1 The cellular composition of infiltrating lymphoid cells in myositis 
To determine whether specific, antigen-driven, B-cell adaptive immune responses were 
occurring in situ, we used the methods described in section 2 to study the cellular 
composition of muscle infiltrating cells in twelve different muscle samples (2 DM, 9 PM, 1 
IBM); we also examined their Ig V-gene repertoire and the processes of somatic 
hypermutation and clonal diversification of the rearranged V-genes. In contrast with other 
autoimmune diseases (see above), no classical ectopic germinal centre structures were 
observed within the inflamed muscle; instead, muscle–infiltrating cells were present in 
cellular aggregations which varied from loose to dense in the appropriate 
perivascular/perimysial or endomysial locations, as in previous studies. B-cells were a 
significant component of the inflammatory infiltrate in all samples examined for all three 
myositis subsets, either as CD20+ B-cells or differentiated plasma cells (Figure 7A-D), 
although the most significant infiltration of CD20+ B-cells was observed within the muscles 
of the two DM patients. FDCs were rare, and were seen only in one IBM and three PM 
samples, and not at all in DM. In addition to these cell phenotypes, CD3+, CD4+, CD8+, 
CD68+ and FoxP3+ cells were also present. Double immunofluorescence staining of cell 
phenotypes with the proliferating cell marker Ki67 identified proliferating cells within the 
infiltrating population. In addition to CD20+ B-cells (Figure 7E & F), proliferating CD3+, 
CD4+, CD8+ and CD68+ cells were observed, as well as FoxP3+ cells in one DM patient.  
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Fig. 7. Immunohistochemical staining of antigen-specific muscle-infiltrating B-cells and 
plasma cells. 
A – D: Infiltrating B-cells and plasma cells (red) within inflamed muscle; E & F: Proliferating B-cells 
(CD20+ B-cells – Fluorescein-Avidin D (green), Ki67+ - Texas Red-Avidin D (red)). Slides A, B, C & E are 
from 2 DM patients; D & F are from a PM patient. Original magnification for images A - D: 400x; E & F: 
630x. Scale Bar (E & F) represents 15 µm. Arrows indicate double positive staining. 
4.2.2 The Ig V-gene repertoire and clonally proliferating, muscle-infiltrating B-cells 
Analysis of the repertoire of rearranged Ig V-genes expressed by infiltrating B-cells and 
plasma cells revealed significant biases for and against individual gene segments and 
families relative to the normal peripheral blood B-cell and the germline gene repertoires. V-
gene usage varied between patients and myositis subsets and, in a few instances, differed 
significantly between the DM and PM subsets. Interestingly, naïve or unmutated B-cells (0-2 
mutations per VH gene) constituted almost 50% of the B-cells in DM, but <10% in PM, where 
a large proportion of sequences was highly mutated (c.30% >20 mutations). As expected, 
mutations were prevalent within CDRs 1 & 2. A total of nine clonally related sequences was 
found in five of the IM patients studied; 2 DM and 3 PM patients, each with up to four 
different clones comprising between two and ten clonal variants (Figure 8). These clonally 
related sequences provide evidence for specific, antigen-driven B-cell immune responses 
within the inflamed muscle. However, using the method of Hershberg et al. (2008), we 
found no evidence of positive selection in the CDRs of clonally related sequences, nor in any 
sequences isolated from the DM patients, and only in a small percentage from the PM 
patients. Finally, using biotinylated recombinant antigens, we identified antigen-specific B 
and plasma cells in infiltrates from the five out of twelve patients whose autoantibody 
specificities were known, including Jo-1 (Figure 9). 
Parallel studies (Bradshaw et al., 2007) also demonstrated B-cell responses in muscle of 3 
DM, 2 PM and 7 IBM patients but very few CD19+ or CD20+ cells were observed, the 
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majority of B-lineage cells being CD138+ plasma cells that had class switched to either IgG or 
IgA. Clonally related sequences were isolated from whole muscle sections from ten of the 
twelve myositis patients, with up to four different clonal sets isolated from each muscle 
sample. Further studies also support the absence of classical ectopic germinal centre 
structures and the clonal expansion and maturation of B-cells within inflamed muscle 
(Salajegheh et al., 2010). Collectively this and our work strongly suggest the participation of 
antigen-specific B-cell immune responses within the muscle.  
 
 
Fig. 8. Oligoclonal expansion of B-cells and plasma cells in inflammatory myopathies 
Representative examples of clonal genealogical trees constructed from sequences isolated from muscle-
infiltrating B-cells and plasma cells in individual patients, representing the minimum number of cell 
divisions required to generate each daughter cell. Clone A from a DM patient; clone B from a PM 
patient. The letters in the circles refer to individual sequences isolated from each B-cell clone. 
Genealogical trees were constructed and  mutations numbered as described in the legend to Figure 5. 
Bracketed figures representing additional silent mutations. Dashed circles represent hypothetical 
intermediates whose sequences were not isolated from the muscle-infiltrating population. 
 
 
Fig. 9. Infiltrating antigen-specific B-cells and plasma cells in inflammatory myopathies 
CD20+ B-cells and antigen-specific cells were visualised by Fluorescein-Avidin D (green) and Texas 
Red-Avidin D (red) respectively. Original magnification was 630X. Arrows identify antigen-specific 
cells within the muscle-infiltrating population of polymyositis patients.  
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As previously described in other autoimmune diseases, a role for B-cells in IM is implied by 
the clinical improvement in patients administered Rituximab® therapy, including 
improvements in muscle strength. Some patients relapsed as their B-cell pools repopulated 
and depletion of autoantibody titres was variable (Chung, Genovese, & Fiorentino, 2007; 
Cooper et al., 2007; Levine, 2005). The potential of B-cells as therapeutic targets is further 
supported by the elevations in serum levels and gene expression of B-cell activating factor 
(BAFF) in IM patients, a cytokine crucial for B-cell maturation and survival, which is also 
thought to play a role in autoantibody production (Krystufkova et al., 2008; Salajegheh et al., 
2010).  
Despite all the evidence described here implicating B-cells and loss of B-cell tolerance in the 
IM, numerous questions still remain to be resolved, including identification of the 
stimulating antigens and epitopes, sequence characteristics and pathogenicity of high-
affinity, antigen-specific antibodies produced in situ, and the factors regulating and 
controlling these autoimmune reactions. The resolution of these questions will enhance our 
understanding of the immune pathology of IM and facilitate the diagnosis, treatment and 
management of these diseases.   
5. The ectopic germinal centre response in breast cancer  
In autoimmune diseases there is a failure of immunological tolerance resulting in an 
immune response to self-antigens, causing pathological damage to the target organ and 
tissues, the nature of the target tissue depending on the specificity of the response. In 
malignancy the immune response, if it occurs, is similar in that it is essentially directed 
against self, i.e. tumour-associated, antigens. These antigens may be mutated, altered by 
metabolic processes, or merely aberrantly or over-expressed on the tumour. The problem, 
however, is converse to autoimmune disease in that, whereas in autoimmune disease the 
aim is to suppress the immune response, preferably specifically against the target organ, in 
cancer the hope is that it will be possible to boost the immune response which is often too 
weak to overcome the rapidly growing tumour. 
Several autoimmune disorders sometimes associate with certain tumours, most often small 
cell lung cancer, breast or ovarian carcinomas, ovarian teratomas, neuroblastomas and 
lymphomas (with Sjögren’s syndrome), reviewed by Lang & Vincent and Rosenfeld et al. 
(Lang & Vincent, 2009; Rosenfeld & Dalmau, 2010). In the examples studied, the target 
autoantigen(s) are expressed on the tumour which seems to autoimmunise against them. 
Indeed, if the tumour is removed, autoantibody levels often decline (Chalk et al., 1990). In 
many syndromes, the autoimmune disorder serves as a valuable early warning of the 
associated tumour, and may even slow its growth (Maddison & Lang, 2008). 
5.1 Pathology of breast cancer  
Breast cancer is the second most common malignancy in women, accounting for 31% of all 
types of cancer, with a lifetime incidence in the U.K. of 1/8 in women and c.1/1000 in men. 
Despite advances in screening, diagnosis and therapy, 12,000 women die of breast cancer 
each year in the U.K. and the global incidence in females is 23%, but there are marked 
variations between different regions, it being the highest in Western Europe, Australia, New 
Zealand and North America. The incidence is relatively low in Asian and African countries 
(figures from Cancer Research UK). There are several different histopathological types of 
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breast cancer, of which the major types are the ductal and lobular carcinomas, either of 
which can be in situ or invasive, the in situ type being considered a possible precursor of 
invasive carcinoma. Ductal and lobular carcinomas in situ are confined to the mammary 
ducts and lobules and have a very high cure rate, approaching 100%. Invasive carcinomas 
account for the majority of breast cancers and have a much poorer prognosis. Malignant cell 
growth appears to start in the ducts and lobules and then invades the surrounding tissues 
and ultimately metastasises to other tissues and organs. A less common type is medullary 
carcinoma, comprising only c.1 – 5% of breast cancers; this typically has heavy infiltrates of 
B-lymphocytes and a significantly better prognosis than the invasive ductal and lobular 
types. Length of disease free survival in breast cancer is unpredictable, with relapse 
occurring up to ten years post treatment and even beyond; it has been postulated that this 
may be due to host factors, including the nature and extent of the immune response.  
5.2 The immune response to breast cancer 
Most breast cancers contain infiltrates of lymphoid cells with large numbers of T-cells, 
including CD4+ and CD8+ T-cells, and variable numbers of B-cells, natural killer cells and 
macrophages. The degree of infiltration varies between different types of breast cancer with 
extensive lymphoid cell infiltrates in ductal carcinoma in situ and some invasive ductal and 
lobular carcinomas (Ben Hur et al., 2002). Most studies have focused on the role of cytotoxic 
T-cells in tumour immunity, with variable success in attempting to suppress tumour growth 
by boosting the T-cell response to tumour-associated antigens. Relatively few studies have 
addressed the role of B-cells and humoral immunity in response to cancers, including breast 
cancer, despite the observation that c.40% of ductal breast carcinomas have significant B-cell 
infiltration. 
There is increasing evidence that B-cells play important dual opposing roles in the immune 
response to tumours; on the one hand as antigen presenting cells and producers of cytotoxic 
antibodies effective at killing tumour cells by antibody-dependent cell-mediated cytotoxicity 
(ADCC) and complement-dependent cell lysis, and as tumour antigen-presenting cells 
capable of very efficient T-cell activation; on the other hand as promoters of inflammation 
aiding tumour progression (de Visser, Korets, & Coussens, 2005; de Visser, Eichten, & 
Coussens, 2006). These seemingly contradictory effects may be due to the difference 
between a specific, high affinity immune response to antigen versus a low affinity, 
polyclonal response, or even suppression of the cytotoxic immune response via regulatory 
B-cells (Mauri, 2010). The importance of antibodies in eliminating tumours is clearly 
demonstrated by the results of treatment of breast cancer patients with humanised 
monoclonal antibodies (MAbs) specific for the epidermal growth factor receptor HER-2 
(trastuzumab/herceptin and pertuzumab). Not only is herceptin effective in slowing down 
the progression of established metastatic disease, it has also recently been demonstrated to 
prevent the emergence of metastases when given as an adjuvant treatment (Hortobagyi, 
2005). Pertuzumab has also yielded promising results in clinical trials (Bianco, 2004). 
Synergistic effects between herceptin and pertuzumab suggest promising new approaches 
to therapy using cocktails of antibodies (Nahta, Hung, & Esteva, 2004) and elucidation of the 
molecular structure of the herceptin Fab/HER-2 complex (Cho et al., 2003) allows rational 
design of therapeutic anti-HER-2 antibodies. MAbs specific for other tumour-associated 
antigens (TAAs) are needed to work synergistically with trastuzumab and to treat patients 
who do not overexpress HER-2.  
www.intechopen.com
 
Autoimmune Disorders – Current Concepts and Advances from Bedside to Mechanistic Insights 
 
418 
Several molecules have been identified that are either over-expressed, mutated, or structurally 
modified on tumour cells and are therefore potential targets for immunotherapy, including 
HER-1, HER-2, MUC-1 and p53 (Taylor-Papadimitriou et al., 2002). Some TAAs appear to 
overcome tolerance and induce a natural immune response as a result of mutation or altered 
expression; humoral immune responses to these antigens in breast cancer patients are 
associated with better early disease stage-specific survival (Angelopoulou et al., 2000;Visco et 
al., 2000; von Mensdorff-Pouilly et al., 2000) and anti-MUC-1 antibodies are cytotoxic to 
tumour cells (Snijdewint et al., 2001). TAA-specific tumour infiltrating (TIL) B-lymphocytes 
and recombinant antibodies have been isolated from both tumour (Kotlan et al., 2000; Kotlan et 
al., 2005) and lymph nodes (Petrarca et al., 1999; Rothe et al., 2004) of medullary and ductal 
carcinoma patients, showing that they are responding specifically to the tumour. Evasion of 
the immune response by the tumour can be overcome by passive immunotherapy or active 
immunisation regimes. B-cells actively responding in the draining lymph node and tumour 
are therefore ideal sources to study the immune response to the tumour and provide the most 
relevant source of potentially therapeutic antibodies. 
5.3 Ductal carcinoma infiltrating lymphocytes are clustered into germinal centres 
We and others found infiltrating lymphocytes in ductal carcinomas were aggregated into 
clusters containing T-cells, B-cells and follicular dendritic cells with plasmablasts/plasma 
cells in and around the aggregates (Coronella et al., 2002; Nzula, Going, & Stott, 2003a). 
These cell clusters appeared to be similar to those seen in the target tissues of autoimmune 
diseases except that there was no mantle zone (also absent in the salivary glands of patients 
with Sjögren’s syndrome (Stott et al., 1998)), so we examined whether they were responding 
as germinal centres. 
5.4 The Ig V-gene repertoire and clonal proliferation of B-cells in ductal carcinoma 
We cloned and sequenced 401 rearranged Ig VH-genes from microdissected tumour-
infiltrating B-cell foci of 7 patients with invasive ductal carcinoma and 271 VH-genes from 
paired sentinel lymph nodes of 3 of the patients. 15 sets of VH-genes from clonally related B-
cells within individual foci were identified by their shared VH, D, JH and CDR3 sequences, 
showing that proliferating, mutating B-cell clones were present in lymphoid foci and that 
these foci were undergoing a germinal centre response within the tumour, similar to the 
ectopic germinal centres we have observed in the target tissues of autoimmune diseases 
(Fig. 10). There was preferential usage of certain VH, D & JH exons, indicating selection of B-
cells expressing antigen receptors encoded by these gene combinations. VH & VL-genes from 
proliferating B-cell clones contained numerous mutations, demonstrating that the somatic 
hypermutation machinery was switched on within the cell cluster, again characteristic of a 
germinal centre response. Analysis of the pattern of mutations showed that the B-cell clones 
are undergoing an antigen-driven response accompanied by selection of specific mutations 
and affinity maturation in situ. Clone founder cells were of both naïve and memory B-cell 
type, showing that a secondary response involving memory B-cells was taking place, but 
also new B-cells that had not previously encountered antigen moved into cell clusters and 
were stimulated by antigen. We also cloned rearranged VH-genes from microdissected 
germinal centres in the paired sentinel lymph node and identified proliferating, 
hypermutating B-cell clones there too. These also revealed selection for particular VH & JH-
genes showing selection by antigen for B-cells expressing these genes during the immune 
response but we did not find evidence that members of the same B-cell clones had migrated 
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from the sentinel node to the tumour; this could have been due to insufficient sample sizes  
(Nzula, Going & Stott, 2003a; Simsa et al., 2005). 
 
 
Fig. 10. Examples of proliferating, hypermutating B-cell clones from the breast tumours of four 
ductal carcinoma patients. 
The best matching germline VH-gene is shown at the origin of each tree. The founder rearranged VH-genes 
of three of these B-cell clones already appear to be mutated, implying that they originated from memory B-
cells, whereas clone A1 appears to have been founded by a naïve B-cell. Genealogical trees were 
constructed and mutations numbered as described in the legend to Figure 5. Reproduced from Nzula et al. 
(2003). 
5.5 Cloning and characterisation of scFv antibodies 
In order to identify the antigens driving the immune response within the tumour, we 
reconstructed the antigen receptors expressed by germinal centre B-cells as scFv antibodies 
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by cloning VH and VL-genes into phagemid (pHEN2), as described in section 2.3, to generate 
scFv-phage libraries expressing randomly assorted combinations of VH and VL-genes. These 
“mini-libraries” were made from the B-cells in individual germinal centres within the 
tumour and are therefore much smaller and more restricted than the very large libraries 
normally made by random combination of large pools of VH and VL-genes. Two scFv-phage 
mini-libraries were constructed from a germinal centre incorporating all the VH-genes 
pooled from the largest proliferating B-cell clone (D4 in Fig. 10) linked randomly to either 
the rearranged Vǋ-genes or the rearranged Vǌ-genes amplified from the same germinal 
centre. 
Tumour-binding scFv were selected from the mini-libraries by three or four cycles of 
panning and elution on a heterologous tumour homogenate pooled from breast tumours of 
5 patients. During the panning cycles we observed exponential enrichment of the Vǌ mini-
library, but not the Vǋ mini-library, indicating that scFv within the Vǌ mini-library bind 
specifically to tumour-associated antigens (Fig. 11A). This is consistent with the scFv-
libraries being derived from the same B-cell clone, since a single B-cell clone uses either a ǋ 
or ǌ light chain, not both. 13 scFv-phages binding to the tumour extract were cloned and 
their specificity for tumour tissue confirmed by ELISA. 7 scFv-phage clones that bound to 
the tumour extract were identified for further characterisation. All 7 used the same 
combination of VH3-23 with exons D1-26 & JH2, expressed by B-cell clone D4, and the light 
chain gene Vǌ1c with Jǌ3b. 
We also constructed two scFv-phage libraries from DNA extracted from a whole sample 
of tumour tissue, as described for the mini-libraries. The 2 libraries were panned on the 
same heterologous tumour homogenate as used with the mini-libraries. After 4 cycles of 
panning we observed an enrichment of several logs for both libraries, indicating the 
presence of tumour-specific antibodies (Fig. 11B). The enrichment of both global libraries 
shows that tumour-specific B-cells derived from independent B-cell clones were present in 
the tumour, as expected. 19 scFv-phages were cloned from the 2 global libraries and their 
specificity for tumour tissue confirmed by ELISA using the same tumour homogenate as 
source of antigen. 
5.6 Identification of the specificity of proliferating B-cells 
Since the scFvs from the VH/Vǌ mini-library were derived from proliferating B-cell clone D4, 
their sequences and antigen specificities reveal the nature of the genes and antigen receptor 
specificities of the original germinal centre B-cells. We therefore sequenced the scFv clones 
that showed the strongest binding to the tumour extract and performed a Blast search of the 
Genbank gene database. The VHDJH heavy chain gene used by all members of B-cell clone 
D4 exhibited 89% homology with a human anti-HER3 MAb (AF048774) and the VǌJǌ light 
chain gene, also used by the same B-cells, matched a human anti-EGFR antibody 
(DQ666353.1) with 96% homology. These, and scFvs from the global libraries, were tested 
for binding to recombinant antigens from the epidermal growth factor receptor family: 
HER-2, HER-3 and HER-4, kindly provided by Genentech (San Francisco, USA) and 
Pharmexa A/S (Hørsholm, Denmark) by ELISA. Six scFvs from B-cell clone D4 and one 
from the global tumour library bound to recombinant HER-2, HER-3 & HER-4, indicating 
that they recognised a shared epitope expressed by all three members of this EGFR family of 
receptors (Fig. 12). Specificity for HER-2, HER-3 & HER-4 was confirmed using soluble scFv 
produced in the non-suppressor strain of E.coli. 
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B 
Fig. 11. Exponential enrichment of scFv-phage after panning and elution on a breast tumour 
extract 
A. VH/Vǋ and VH/Vǌ scFv mini-libraries, using VH-genes from B-cell clone D4, panned on pooled 
heterologous tumour extract The eluate from each panning was then subjected to further cycles of 
panning and elution; B. Global VH/Vǋ and VH/Vǌ scFv-phage libraries from a human breast tumour, 
panned on the same heterologous tumour extract as in A. 
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Fig. 12. EGFR family specificity of scFv antibodies cloned from a mammary carcinoma 
germinal centre. 
Individual scFv-phage (80, 96, 14 & 107 & 120) from B-cell clone D4, proliferating and mutating in a 
breast tumour, and scFv-phage (471), cloned from whole breast tumour tissue, bind to members of the 
epidermal growth factor receptor family Her-2, Her-3 & Her-4. 
5.7 Conclusions 
Clusters of B-cells, T-cells and follicular dendritic cells form within human ductal breast 
carcinomas, resembling the ectopic germinal centres observed in the target tissues of 
patients with autoimmune diseases. These clusters of lymphoid cells contain clones of 
proliferating B-cells that are undergoing somatic hypermutation of their rearranged, Ig V-
(D)-J-genes and affinity selection of their B-cell receptors driven, in the case described here, 
by members of the epidermal growth factor receptor family, viz. HER2, HER3 and HER4. 
The antibodies produced during this response recognise an epitope shared by these 3 cell 
surface receptors, which are known to be overexpressed on breast carcinoma cells and 
several other types of carcinoma, including ovarian cancer. It is very probable that other 
tumour associated antigens are also able to stimulate a local B-cell response within the 
tumour, e.g. antibodies specific for a ganglioside were cloned from medullary carcinoma B-
cells, although it is not clear whether these are involved in attacking the tumour (Kotlan et 
al., 2005).  
Single chain Fv antibodies cloned from tumour germinal centre B-cells can readily be 
converted to complete antibodies by splicing their V-genes on to Ig constant regions of any 
desired isotype. These fully human antibodies can be produced in large quantities in a 
protein expression system and are therefore potential candidates for diagnosis, monitoring 
and therapy of breast and other types of cancer. 
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6. General conclusions 
It has become increasingly clear that infiltrating B- and T-lymphocytes organise themselves 
into ectopic lymphoid follicles and germinal centres within tissues undergoing 
inflammatory processes. This has been observed in several autoimmune diseases (Table 1), 
usually within the target organ or tissue, myasthenia gravis being the exception to the rule 
for reasons discussed in section 3.5. However, ectopic g.c.s are not restricted to autoimmune 
diseases but can also develop in other chronic inflammatory diseases, such as Crohn’s 
disease and ulcerative colitis; at sites of infection such as the liver during chronic hepatitis C 
virus infection and the skin of oncocerciasis patients (Brattig et al., 2010); and in neoplasias, 
including lymphoma of the mucosal-associated lymphoid tissue associated with Sjögren’s 
syndrome (Bombardieri et al., 2007a) and, as shown here, in breast cancer (Table 1). 
How these ectopic g.c.s develop, their role in the pathology of autoimmune diseases, and in 
combating infections and malignancies is still unclear but evidence is beginning to emerge. 
Cytokines, chemokines and signalling molecules involved in lymphoid neogenesis in the 
secondary lymphoid organs also appear to be required for ectopic g.c. formation, including 
lymphotoxins-ǂ, ǃ and ǂ1ǃ2, TNFǂ, Grb2, the chemokine receptor CXCR5, its ligand 
CXCL15, and the B-cell attracting chemokines CXCL13 and CCL21, in this case due to 
release of these molecules within the inflammatory environment, suggesting that g.c. 
formation may be secondary to inflammation (Aloisi & Pujol-Borrell, 2006).  
When reports first emerged of germinal centre-like structures within the target tissues of 
autoimmune diseases, there was some scepticism regarding whether these structures were 
involved in true germinal centre reactions. These doubts have now been dispelled. 
Identification of dark and light zones and a follicular dendritic cell network in intimate 
contact with B-cells was highly suggestive of a germinal centre reaction, especially when it 
was shown that autoantigen was trapped on the follicular dendritic cell processes, e.g. 
(SHIONO et al., 2003). Studies by us and other researchers have shown that the B-cells 
within ectopic germinal centres are activated to antigen-driven clonal proliferation, somatic 
hypermutation and class switching, similar to the response in orthotopic g.c.s responding to 
foreign antigens. That they switch on the somatic hypermutation machinery has been shown 
in several autoimmune diseases by sequencing studies of the expressed, rearranged Ig V-
genes cloned from microdissected g.c.s. This has been confirmed in the salivary gland g.c.s 
of Sjögren’s patients and the synovial g.c.s of rheumatoid arthritis patients by identification 
of activation induced cytidine deaminase (AID), a key enzyme in somatic hypermutation 
and class switch recombination (Bombardieri et al., 2007b; Humby et al., 2009). Interestingly, 
expression of AID has recently been observed in hyperplastic fibroblasts of rheumatoid 
arthritis patients (Igarashi et al., 2010). Expression correlated with mutations in the p53 gene 
and was induced by TNFǂ in vitro. AID is known to induce mutations in non-Ig genes at a 
lower frequency and it was suggested that the mutations of this tumour suppressor gene 
may be the cause of the fibroblast hyperplasia. Affinity maturation of B-cell receptors during 
somatic hypermutation has been demonstrated by analysis of replacement mutations, 
although early analyses failed to take into account the bias towards replacement mutations 
in the CDRs resulting from targeting of AID to sequence motifs such as RGYW. Final 
confirmation requires direct affinity measurements of autoantibodies cloned from germinal 
centre B-cells and/or by 3-D molecular modelling of the antigen-binding site bound to its 
epitope, as we have shown for anti-hen egg lysozyme antibodies produced in an orthotopic 
germinal centre reaction (Adams et al., 2003). 
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In several cases it has been shown that the autoantibodies generated in ectopic g.c.s have 
similar specificities to the autoantibodies found in the blood, notably in Hashimoto’s 
thyroiditis, Sjögren’s syndrome and rheumatoid arthritis, suggesting that the g.c.s 
contribute to pathological mechanisms, although whether they are critical in the early stages 
of development of the disease, or only contribute to its maintenance once the initial tissue 
damage has commenced, has yet to be established. Production of cytokines and chemokines 
at sites of damage that attract lymphocytes and contribute to lymphoid neogenesis suggests 
that the latter may be the more likely scenario. Nevertheless, a detailed understanding of the 
mechanisms involved in generation of ectopic g.c. structures and maintenance of production 
of plasma cells and memory B-cells producing potentially pathogenic antibodies is essential 
for a full understanding of the pathology of autoimmune disease and holds promise for 
developing new methods of therapy, based on controlling this response or inducing 
immunological tolerance to the autoantigens. 
Even more work needs to be done to determine the role of ectopic g.c.s in other diseases, 
including sterile and infectious chronic inflammatory diseases and cancer. What other types 
of cancer, in addition to breast cancer and lymphoma, induce germinal centre reactions 
within the tumour and the nature of their response in elimination of cancer cells have yet to 
be determined. The identification of intra-tumour g.c.s producing antibodies and memory B-
cells with specificity for members of the epidermal growth factor receptor family holds out 
hope that therapeutic vaccines can be developed to boost this response for therapy of breast 
cancer and, potentially other neoplasias, such as ovarian cancer, in which these molecules 
are overexpressed. Experimental approaches using mouse models of breast cancer support 
this optimism (Renard et al., 2003; Renard & Leach, 2007; Mukhopadhyay, MS in 
preparation). Cloning of antibodies against tumour-associated antigens from intra-tumour 
g.c.s is also a novel way of producing fully human antibodies for passive immunotherapy. 
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